- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
VistaGen Therapeutics Inc (VTGN)
VistaGen Therapeutics Inc stock price live, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the VistaGen Therapeutics Inc real time stock price chart below.
What Is the VistaGen Therapeutics Inc Stock Price Today?
The VistaGen Therapeutics Inc stock price today is 2.955.
What Is the Stock Symbol for VistaGen Therapeutics Inc?
The stock symbol for VistaGen Therapeutics Inc is ""VTGN.""
What Stock Exchange Does VistaGen Therapeutics Inc Trade On?
VistaGen Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is VistaGen Therapeutics Inc a Good Stock to Buy?
Determining whether VistaGen Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VTGN quote. (ISIN: US92840H4002)
What Is the VistaGen Therapeutics Inc Stock Price Today?
The VistaGen Therapeutics Inc stock price today is 2.955.
What Is the Stock Symbol for VistaGen Therapeutics Inc?
The stock symbol for VistaGen Therapeutics Inc is ""VTGN.""
What Stock Exchange Does VistaGen Therapeutics Inc Trade On?
VistaGen Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is VistaGen Therapeutics Inc a Good Stock to Buy?
Determining whether VistaGen Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VTGN quote. (ISIN: US92840H4002)
NASDAQ
Currency in USD
Fair Value
An estimate of a VistaGen Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.820
3.000
52 wk Range
1.900
3.790
VTGN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VTGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a VistaGen Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8203.000
52 wk Range
1.9003.790
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VTGN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a VistaGen Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
13.000
Upside
+339.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form 8K VistaGen Therapeutics Inc For: 25 June
- Investing.com
- Form 8K VistaGen Therapeutics Inc For: 25 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
VistaGen Therapeutics Inc Company Profile
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company’s clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
VistaGen Therapeutics Inc Earnings Call Summary for Q1/2026
- R&D expenses rose to $11.7M, net loss increased to $15.1M, but cash reserves remain strong at $63.2M
- Awaiting critical Phase III trial results for Facadeinol (SAD treatment) in Q4 2025, positioning as first-mover
- Stock closed at $2.73, down 8.08%; company appears undervalued per InvestingPro analysis
- New Chief Corporate Development Officer appointed; focus on long-term growth through innovative pipeline
- EPS forecast of -$2.03 for FY2026; profitability not expected this year despite 100% gross profit margin
Last Updated: 08/08/2025, 12:04
Read Full TranscriptCompare VTGN to Peers and Sector
Metrics to compare | VTGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVTGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −1.2x | −0.5x | |
PEG Ratio | 0.05 | −0.05 | 0.00 | |
Price/Book | 1.6x | 2.7x | 2.6x | |
Price / LTM Sales | 140.3x | 8.3x | 3.3x | |
Upside (Analyst Target) | 306.1% | 301.3% | 40.6% | |
Fair Value Upside | Unlock | 15.6% | 5.3% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.000
(+339.93% Upside)
Earnings
Latest Release
Jun 17, 2025
EPS / Forecast
-0.44 / -0.85
Revenue / Forecast
-15,000.00 / 180.00K
People Also Watch
FAQ
What Stock Exchange Does VistaGen Therapeutics Trade On?
VistaGen Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for VistaGen Therapeutics?
The stock symbol for VistaGen Therapeutics is "VTGN."
What Is the VistaGen Therapeutics Market Cap?
As of today, VistaGen Therapeutics market cap is 90.20M.
What Is VistaGen Therapeutics's Earnings Per Share (TTM)?
The VistaGen Therapeutics EPS (TTM) is -1.79.
From a Technical Analysis Perspective, Is VTGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has VistaGen Therapeutics Stock Split?
VistaGen Therapeutics has split 3 times.
How Many Employees Does VistaGen Therapeutics Have?
VistaGen Therapeutics has 57 employees.
What is the current trading status of VistaGen Therapeutics (VTGN)?
As of 15 Aug 2025, VistaGen Therapeutics (VTGN) is trading at a price of 2.96, with a previous close of 2.93. The stock has fluctuated within a day range of 2.82 to 3.00, while its 52-week range spans from 1.90 to 3.79.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.